Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Elisabeth E. Fransen van de Putte,Luna van den Brink, Mohamed A. Mansour,Johannes C. van der Mijn,Sofie Wilgenhof,Johannes V. van Thienen,John B.A.G. Haanen,Ekaterini Boleti, Thomas Powles,Patricia J. Zondervan,Niels M. Graafland,Axel Bex

European Urology Open Science（2023）

Cited 1|Views23

No score

Abstract

Following ipilimumab/nivolumab treatment, cytoreductive nephrectomy to achieve no evidence of disease resulted in durable disease-free survival and median treatment-free survival of 21 mo.

Translated text

Key words

deferred cytoreductive nephrectomy,systemic therapy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined